Prosecution Insights
Last updated: July 17, 2026
Application No. 18/704,557

COMPOSITIONS COMPRISING CATIONIC ALPHA-1,6-GLUCAN DERIVATIVE AND ALPHA-1,3-GLUCAN

Non-Final OA §103
Filed
Apr 25, 2024
Priority
Nov 05, 2021 — provisional 63/276,163 +3 more
Examiner
OLSON, ANDREA STEFFEL
Art Unit
Tech Center
Assignee
Nutrition & Biosciences USA
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
50%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
881 granted / 1415 resolved
+2.3% vs TC avg
Minimal -12% lift
Without
With
+-12.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
47 currently pending
Career history
1471
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
55.5%
+15.5% vs TC avg
§102
8.6%
-31.4% vs TC avg
§112
6.0%
-34.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1415 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This application is a national stage application of PCT/US2022/048939, filed November 4, 2022, which claims benefit of provisional applications 63/354501, filed June 22, 2022, 63/354505, filed June 22, 2022, and 63/276163, filed November 5, 2021. Claims 1-18 are pending in this application and examined on the merits herein. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-18 are rejected under 35 U.S.C. 103 as being unpatentable over Miller et al. (PCT international publication WO2022/203866, Reference included with PTO-892) in view of Huang et al. (PCT international publication WO2018/112187, Reference included with PTO-892) Independent claim 1 is directed to a composition comprising both a positively charged alpha-1,6-glucan and an insoluble alpha-1,3-glucan. Miller et al. discloses a fabric care composition comprising a dextran polymer functionalized with quaternary ammonium groups. (p. 1 paragraph 6) These compositions are used as fragrance deposition aids in a method of treating laundry. (p. 1 paragraph 7) More specifically the dextran polymer is an alpha glucan having about 94-96% alpha-1,6 linkages and about 4-6 mol% alpha-1,3 linkages, as well as pendant quaternary ammonium groups. (p. 4 paragraph 17 – p. 6 paragraph 19) In a specific embodiment the polymer is seen to have a degree of substitution of 0.19 and a mw of about 1820 kDa. (pp. 13-14 paragraph 42) This polymer therefore falls within the scope of polymer (a) recited in present claim 1-4. Miller et al. does not further describe the composition as also including an insoluble alpha-1,3-glucan. Huang et al. discloses a composition comprising a poly-alpha-1,3 glucan having at least 50% alpha-1,3 linkages. (p. 2 lines 15-20) in a preferred embodiment the poly-alpha-1,3-glucan has a degree of polymerization of at least 10. (p. 19 lines 19-22) These polysaccharides can be used as components of fabric care compositions, for methods of treating fabrics. (p. 6 lines 10-16, p. 41 lines 26 – p. 43 line 4) It would have been obvious to one of ordinary skill in the art at the time of the invention to produce a fabric care composition containing both the quaternary ammonium alpha-1,6-glucan polymer described by Miller et al. and the insoluble alpha-1,3-glucan polymer described by Huang et al. One of ordinary skill in the art would have seen the prior art as suggesting that both of these polymers are useful ingredients to include in such a composition. Regarding claims 6, 7, and 9, Miller et al. discloses a preferred formula for the quaternary ammonium that is an ether group. (pp. 5-6 paragraph 19) The quaternary ammonium can further include a C6-22 alkyl group, which substantially overlaps the C4-20 recited in present claim 7. Regarding claim 10, Huang et al. describes the poly alpha 1,3 glucan as having at least 95% alpha-1,3- glycosidic linkages. (p. 20 lines 6-8) Regarding claim 11, Huang et al. teaches a Dp of about 500-900. (p. 19 lines 21-22) Regarding claim 12, Miller discloses that the fabric care composition is an aqueous composition. (p. 3 paragraph 13) Regarding claim 8, Huang et al. discloses antimicrobial activity. (p. 45 lines 11-16) Additionally, a property such as antimicrobial activity is reasonably expected to be an inherent property of a particular chemical structure and would therefore be necessarily present. Regarding claims 14, 15, and 18 these claims would be infringed by treating a fabric with the fabric care composition, which is necessarily suggested by its disclosed utility. Regarding claim 16-17, Huang et al. specifically suggests a process of washing soiled fabric using the disclosed composition. Therefore the invention taken as a whole is prima facie obvious. Conclusion No claims are allowed in this action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREA OLSON whose telephone number is (571)272-9051. The examiner can normally be reached M-F 6am-3:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Y Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREA OLSON/ Primary Examiner, Art Unit 1693 6/15/2026
Read full office action

Prosecution Timeline

Apr 25, 2024
Application Filed
Jun 18, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673070
TREATMENT OF SEPSIS AND HYPERCYTOKINEMIA
3y 9m to grant Granted Jul 07, 2026
Patent 12668790
LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS
4y 3m to grant Granted Jun 30, 2026
Patent 12668577
COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS
3y 2m to grant Granted Jun 30, 2026
Patent 12668669
Method for Preparing Cellulose and Lignin Oil by Depolymerizing Lignocellulose Without Exogenous Hydrogen
3y 3m to grant Granted Jun 30, 2026
Patent 12662494
OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE
5y 4m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
50%
With Interview (-12.2%)
3y 1m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1415 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month